VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfoli...
Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced that it has entered into a drug discovery se...
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (af...
Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cance...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering fr...
Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Trav...
Adragos Pharma, a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, has announced the acquisition of Baccinex, a...
GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...
© 2025 Biopharma Boardroom. All Rights Reserved.
